本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
The brand will preview its upcoming Gesture Control feature, which leverages advanced computer vision to control the camera with arm movements LAS VEGAS, Jan. 5, 2024 /PRNewswire/ -- Zero Zero Robotics, experts in user-friendly devices featuring machine vision and precise control systems, is excited to announce its participation at the 2024 Consumer Electronics Show (CES) in Las Vegas. They are set to showcase their best-selling HOVERAir X1 pocket-sized 2.7K self-flying camera at the Venetian Expo Halls A-D, Global Pavilions, booth no. 55745 from January 9 - 12, 2024. Attendees will get a first look at the camera's new Gesture Control feature, a breakthrough in user interaction that utilizes advanced computer vision to direct the camera through simple arm movements. Fun-Filled Flight, Zero Zero at CES 2024 2023 marked a significant milestone for HOVERAIR X1, with the initial Indiegogo campaign generating overwhelming support, attracting over 5,000 backers and raising $1.8M USD. This success was followed by a robust direct sales launch, and subsequent introductions on Amazon USA, Canada, and Australia. To date, the HOVERAIR X1 has sold tens of thousands of units across nearly 40 countries. Meet HOVERAir in Real Life Weighing a mere 125g, HOVERAir X1 is a lightweight device that frees users from the hassles of registration in most parts of the US, thanks to its compact design. The HOVERAir X1 epitomizes the fusion of fun, portability, and performance. Launching effortlessly from the palm within seconds, it offers a suite of autonomous flight modes, ensuring crisp visuals, stabilized recordings, and uniquely, outstanding audio clarity, all housed within a safety-first, cage-like design. "We're excited to bring HOVERAir X1 to CES this year and introduce our new Gesture Control feature which levels up the ability of users to easily and intuitively create unique and creative videos," said MQ Wang, Founder & CEO of Zero Zero. "This new technology is a testament to our commitment to pushing the boundaries, enhancing the user experience, and opening up new creative possibilities." The device boasts a rapid 3-second launch and landing protocol, springing to action from the palm and returning with equal ease. Its enclosed design prioritizes user safety, while the recording specs, ranging from 2.7K@30fps to 1080P HDR, offer a plethora of high-definition filming options. Features like Burst mode and hybrid stabilization promise fluid, high-quality footage. Its sleek, foldable design makes it the perfect travel companion, fitting seamlessly into pockets or purses. An array of five cinematic flight modes (Hover, Follow, Zoom Out, Orbit, Bird's Eye) offer unique perspectives and are easily activated with a single touch. For those desiring finer control, a dedicated app allows for real-time composition adjustments, editing, and instant sharing on social platforms. The device's cutting-edge computer vision and robust tracking capabilities allow it to follow users at speeds over 15mph. Utilizing Visual Inertial Odometry (VIO) technology and a ToF laser altitude system, it ensures centimeter-level precision, facilitating seamless transitions between indoor and outdoor environments. "Through HOVERAir X1, we aim to redefine the way people capture and share their moments," continued Wang. "Gesture Control is just the beginning of a series of new capabilities we plan to introduce, revolutionizing personal photography and content creation." The HOVERAir X1 defines what a flying camera is—no controller, no app, just intuitive, hands-free operation. With its light frame, enclosed design, and versatile flight modes, this camera is an indispensable tool for capturing life's fleeting moments. Media wishing to experience a live demo of HOVERAir X1 at CES or interview Zero Zero's personnel should contact PR agency representative Borjana Slipicevic. About Zero Zero Zero Zero was co-founded in 2014 by Stanford Phds, MQ Wang and Tony Zhang. Zero Zero specializes in embedded AI technology to create intelligent devices characterized by machine vision and high-precision control systems. Zero Zero's team members are dreamers, engineers, inventors, and builders hailing from top universities and research institutions around the world. Its investors include IDG, ZhenFund, and other top US investors. Zero Zero holds more than 120 core patents and has pioneered new technologies, such as fully enclosed portable propeller design and bi-copter design. CONTACT:Borjana SlipicevicProper Propagandaborjana@properpropaganda.net
兩間公司共同致力創新品質控制流程，以應對規模、數據完整性和加快上市時間等生物製造挑戰 羅威爾，麻薩諸塞州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID)（以下簡稱「公司」）是一間創新生命科學技術公司，提供關鍵任務自動化解決方案，以促進醫療保健產品的高效生產和快速、安全發布。該公司今日宣布 Samsung Biologics (KRX: 207940.KS) 選擇了 Growth Direct® 平台來自動化其微生物品質控制流程，以提高效率、更穩健的數據完整性和可擴展的品質控制操作。 Rapid Micro Biosystems 董事長兼行政總裁 Robert Spignesi 表示：「Samsung Biologics 作為全球領先的合約開發和製造組織 (CDMO)，展示了對生物製藥生產自動化和品質管理的堅定承諾。」「Growth Direct® 提高了品質控制微生物實驗室的營運效率和數據完整性，我們很榮幸能與 Samsung Biologics 合作。」 很多全球製藥商依靠 Growth Direct 平台來滿足當今的微生物品質控制標準和未來的挑戰。它是唯一用於微生物學品質控制測試的全自動、非破壞性生長平台，可提供更快的結果、改進的數據完整性和更高的準確性，並具有更大的樣品容量。 欲了解有關公司和 Growth Direct® 平台的更多資訊，請瀏覽：Rapid Micro Biosystems。 關於 Rapid Micro Biosystems Rapid Micro Biosystems 是一間創新生命科學技術公司，提供關鍵任務自動化解決方案，以促進生物製劑、疫苗、細胞和基因療法以及無菌注射劑等醫療保健產品的高效生產和快速、安全發布。該公司的旗艦產品 Growth Direct 系統對全球最大、最複雜的藥品生產業務中使用的過時的手動微生物品質控制（「MQC」）測試工作流程進行了自動化和現代化改造。Growth Direct 系統將品質控制實驗室搬到了生產車間，釋放出 MQC 自動化的強大威力，以提供客戶所依賴的更快的結果、更高的準確性、更高的營運效率、更好地遵守數據完整性法規，以及更快決策，以確保安全、持續地供應重要的醫療保健產品。該公司總部位於麻薩諸塞州羅威爾，在美國設有生產工廠，全球生產基地位於麻薩諸塞州列剋星敦、瑞士、德國和荷蘭。欲了解更多資訊，請瀏覽www.rapidmicrobio.com 或在 Twitter 上@rapidmicrobio或 LinkedIn上關注該公司。 關於 Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) 是一個全面整合的端到端 CDMO 服務供應商，為我們生產的生物製藥產品提供從細胞系開發到最終無菌灌裝／完成的無縫開發和生產解決方案，以及實驗室測試支援。我們最先進的設施符合 cGMP，配備從小規模到大規模的生物反應器，可滿足不同客戶的需求。為了最大限度地提高我們的營運效率並擴大我們的產能，以滿足不斷增長的生物製造需求，Samsung Biologics 最近完成了 Bio Campus I 的建設，其中 4 號工廠的總產能為 604KL，並啟動了 Bio Campus II 和 5 號工廠的建設，該工廠將於 2025 年 4 月投入營運，新增 184KL 生物製造產能。此外，Samsung Biologics America 使該公司能夠更接近美國和歐洲的客戶。我們透過投資抗體藥物偶聯物 (ADC) 設施、專用 mRNA 生產設施和額外的無菌灌裝能力等技術，不斷提升我們的能力，以滿足客戶的需求。作為首選的永續 CDMO 合作夥伴，我們致力於透過靈活的生產解決方案、卓越的營運和成熟的專業知識，按時、完整地交付我們生產的產品。 前瞻性陳述 本新聞稿包含經修訂的《1933 年證券法》(Securities Act of 1933) 第 27A 條和經修訂的《1934 年證券交易法》(Securities Exchange Act of 1934) 第 21E 條定義的前瞻性陳述。本新聞稿中包含的所有與歷史事實無關的陳述均應被視為前瞻性陳述，包括但不限於有關 Growth Direct 系統對 Samsung Biologics 營運效率和數據完整性的預期影響的陳述。 前瞻性陳述涉及已知及未知風險、不確定性和假設，或會導致實際結果與任何前瞻性陳述明示或暗示的任何結果有重大差異，包括公司於 2023 年 3 月 10 日向美國證券交易委員會（「SEC」）提交的 10-K 表年度報告中「風險因素」標題下概述的重要因素，因為該等因素可能會在向 SEC 提交的其他文件中不時更新，該等文件可在 SEC 網站 www.sec.gov 及公司網站 investors.rapidmicrobio.com 投資者關係頁面上獲取。儘管公司認為其前瞻性陳述中反映的預期是合理的，但無法保證未來的結果。本公司沒有義務且不承擔任何義務更新或修改本新聞稿中的任何前瞻性陳述，以反映自本新聞稿發布之日以來的變化，除非法律另有規定。 Rapid Micro Biosystems 投資者聯絡方式： Michael Beaulieu，特許金融分析師 (CFA) 投資者關係與企業傳訊副總裁 investors@rapidmicrobio.com Rapid Micro Biosystems 媒體聯絡方式: media@rapidmicrobio.com Samsung Biologics 媒體聯絡方式: Claire Kim，行銷傳訊主管 cair.kim@samsung.com
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- Fresh2 Group Ltd. (NASDAQ: FRES) ("Fresh2" or "the Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry, today announced that it has, through its subsidiary Fresh2 Technology Inc., signed a definitive Stock Purchase Agreement (SPA) for the acquisition of Youfood Group Inc., a business-to-customer cross-border e-commerce food platform, which will connect Asian and South American food resources with customers in North America. The acquisition is expected to enhance access to a new customer base. According to the terms of the SPA, Fresh2 has agreed to acquire 100% of the issued and outstanding shares in Youfood in exchange for 38,333,334 newly issued shares of Fresh2 Class A common stock. Haohan Xu, CEO of Fresh2, stated, "We are committed to sustainable development in the food service industry and to continuously bring diverse high-quality food products to North American consumers. This acquisition provides us with an excellent opportunity to integrate and enhance our capabilities, thereby improving performance and expanding our food supply chain ecosystem." About Fresh2 Group Limited Fresh2 Group Limited is engaged in the business-to-business e-commerce and supply chain sectors. Committed to helping restaurants lower procurement costs and improve efficiency, Fresh2 utilizes an advanced supply chain management system. By applying strategic digital technologies and innovative business models, Fresh2 is driving the online transformation of the restaurant supply industry. Fresh2 aims to refine restaurant operations, adding significant value to the food industry, and building a global network of restaurateurs in the digital age. For more information, visit: https://fresh2.co/investors. Safe Harbor Statement This announcement contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, formulated in accordance with the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements, reflecting the Company's projections about its future financial and operational performance, employ terms like 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'target,' 'aim,' 'predict,' 'outlook,' 'seek,' 'goal,' 'objective,' 'assume,' 'contemplate,' 'continue,' 'positioned,' 'forecast,' 'likely,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately,' and similar expressions to convey the uncertainty of future events or outcomes. These forward-looking statements are based on the Company's current expectations, assumptions, and projections, involving judgments about future economic conditions, competitive landscapes, market dynamics, and business decisions, many of which are inherently challenging to predict accurately and are largely beyond the Company's control. Additionally, these statements are subject to a multitude of known and unknown risks, uncertainties, and other variables that could significantly diverge the Company's actual results from those depicted in any forward-looking statement. These factors include, but are not limited to, varying economic conditions, competitive pressures, and regulatory changes. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Combination Creates a Leading Global Integrated Lithium Chemicals Producer Key Strengths Leading global lithium chemicals producer with the resources, scale and expertise to meet growing customer and industry needs − reliably, safely and responsibly. Premier lithium resources and manufacturing sites in key locations globally across the lithium value chain. Highly complementary assets and vertically integrated business model focused on enhancing operational flexibility and predictability while lowering costs. Ability to de-risk and accelerate growth with a world-class pipeline of development projects, proven execution capabilities and technical, capital and projects expertise. Leading sustainability profile, with an unwavering commitment to continuous improvement, decarbonization and delivering greater value to customers, employees, communities and shareholders. PHILADELPHIA and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ -- Arcadium Lithium plc (NYSE: ALTM, ASX: LTM, "Arcadium Lithium") today announced the completion of the all-stock merger of equals between Allkem and Livent. The new, combined company is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. With roughly U.S. $1.9 billion of combined total revenue in 2022 and a global team of more than 2,600 employees, Arcadium Lithium is one of the largest integrated producers of lithium chemicals in the world. Paul Graves, Chief Executive Officer of Arcadium Lithium, said: "As one of the leading global producers of lithium chemicals, Arcadium Lithium has the resources, scale and expertise to meet the growing needs of our rapidly changing industry. We are a leader in every major lithium extraction process – from hard rock mining to conventional pond and DLE-based brine processing – and vertically integrated, from resource to chemical manufacturing, in strategic locations around the world. This will open doors to new opportunities and strengthen our ability to deliver value to our customers, investors, employees and communities." Mr. Graves continued: "It is a privilege for me to lead this great company forward with such an incredible team. This transformational merger would not have been possible without the hard work and commitment of our integration planning teams over the past months. I want to thank them and all of our employees around the world for getting us to this position. Together, we are launching an exciting new company that combines the strengths and storied legacies of two incredible organizations, both with an wavering commitment to safe, responsible and sustainable operations. We look forward to building on this strong foundation and leading our industry forward." Arcadium Lithium ordinary shares will begin trading today on the NYSE under the ticker "ALTM." Arcadium Lithium also maintains a foreign exempt listing on the ASX (via the issue of CHESS Depositary Instruments (CDIs) to Allkem shareholders) and will commence trading on a normal settlement basis on the ASX under the ticker "LTM" at 10:00am (AEDT) on January 5, 2024. Allkem shareholders received either: (a) one Arcadium Lithium ASX listed CDI; or (b) one Arcadium Lithium NYSE listed share depending where they resided and what election (if any) they had made for each Allkem ordinary share held, except for shareholders in certain ineligible jurisdictions, who will receive cash proceeds from the sale of the Arcadium Lithium CDIs in lieu of such CDIs after closing. Livent shareholders received 2.406 Arcadium Lithium NYSE listed ordinary shares for each Livent share held. Arcadium Lithium will have approximately 1,074 million ordinary shares outstanding upon closing. Arcadium Lithium Contacts Investors: Daniel Rosen +1 215 299 6208daniel.rosen@livent.com Phoebe Lee +61 413 557 780phoebe.lee@allkem.co Media:Karen Vizental +54 9 114 414 4702karen.vizental@allkem.co Address:Arcadium Lithium plcSuite 12, Gateway HubShannon Airport HouseShannon, Ireland About Arcadium Lithium Arcadium Lithium is a leading global lithium chemicals producer committed to safely and responsibly harnessing the power of lithium to improve people's lives and accelerate the transition to a clean energy future. We collaborate with our customers to drive innovation and power a more sustainable world in which lithium enables exciting possibilities for renewable energy, electric transportation and modern life. Arcadium Lithium is vertically integrated, with industry-leading capabilities across lithium extraction processes, including hard-rock mining, conventional brine extraction and direct lithium extraction (DLE), and in lithium chemicals manufacturing for high performance applications. We have operations around the world, with facilities and projects in Argentina, Australia, Canada, China, Japan, the United Kingdom and the United States. For more information, please visit us at www.ArcadiumLithium.com. Important Information and Legal Disclaimer: Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this news release are forward-looking statements. In some cases, we have identified forward-looking statements by such words or phrases as "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for Arcadium Lithium based on currently available information. There are important factors that could cause Arcadium Lithium's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including the factors described under the caption entitled "Risk Factors" in Livent Corporation's 2022 Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 24, 2023, and the factors described under the caption entitled "Risk Factors" in Arcadium Lithium's registration statement on Form S-4, initially filed with the SEC on July 20, 2023, as amended thereafter and declared effective by the SEC on November 20, 2023, as well as other risks associated with the merger of equals transaction between Livent Corporation and Allkem Limited that resulted in the creation of Arcadium Lithium, as well as other SEC filings and public communications. Although Arcadium Lithium believes the expectations reflected in the forward-looking statements are reasonable, Arcadium Lithium cannot guarantee future results, level of activity, performance or achievements. Moreover, neither Arcadium Lithium nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Arcadium Lithium is under no duty to update any of these forward-looking statements after the date of this news release to conform its prior statements to actual results or revised expectations. Logo - https://mma.prnasia.com/media2/2310012/4475702/Arcadium_Lithium_Horizontal_Logo.jpg?p=medium600
Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targeting CDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round. The round was co-led by Novo Holdings, OrbiMed, and F-Prime Capital, alongside Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture and others, as well as BioTrack Capital, a co-lead for the Seed Round. OnCusp Therapeutics has raised $139 million since its establishment in April 2021. The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. Additionally, the capital will aid in expanding the OnCusp portfolio and team. CUSP06 has strong preclinical data demonstrating the potential for best-in-class activity. Engineered to increase potency, heighten "bystander effect," elevate linker stability, and overcome drug resistance, CUSP06's differentiating attributes could translate into higher clinical response rates and durability, with an improved safety profile. Having obtained FDA IND clearance in 3Q 2023, CUSP06 will be in a first-in-human Phase I study in the US. "We are grateful to have the trust and support from some of the most prominent global biotech investors," said Dr. Bing Yuan, Co-Founder and CEO of OnCusp Therapeutics. "I am also thankful to the OnCusp team for their commitment and excellent work. We hold a strong conviction to develop innovative oncology therapies for patients. This significant Series A financing enables OnCusp to accelerate the development of CUSP06 and other game-changing therapeutics in our fight against cancer." As part of the financing, OnCusp Therapeutics will appoint Dr. Karen Hong, Partner in the Venture Investments team at Novo Holdings US, Inc., a wholly owned subsidiary of Novo Holdings; Diyong Xu, Principal at OrbiMed; and Dr. Chong Xu, Partner at F-Prime Capital, to the company's Board of Directors. "We are thrilled to have co-led this round. The remarkable progress that the company has made in such a short time is a testament to its highly efficient business model and the team's exceptional execution capabilities," said Dr. Karen Hong. "We share OnCusp's mission in bringing oncology innovations to life and are committed to supporting the company's continued growth and success." "ADCs have become one of the most promising modalities for treating cancer, and CDH6 is emerging as a winning ADC target. We believe CUSP06 is well positioned to unlock the full potential of this target, both in high and low CDH6 expressing tumors," said Diyong Xu. "We also look forward to OnCusp expanding its portfolio to fully leverage its translational and clinical development expertise." "I am excited to join the OnCusp Board at this transformative moment for the company," stated Dr. Chong Xu. "F-Prime is committed to proactively champion breakthrough approaches like CUSP06, which holds immense potential to help patients with ovarian cancer and other advanced solid tumors. I look forward to working with other board members and the executive team to propel OnCusp to its next phase of growth." "As a major investor since the company's inception, I am impressed by the entrepreneurship, commitment, and perseverance exemplified by the OnCusp team in the current challenging biotech market." added Dr. Jiacong Guo, one of OnCusp's current Board Directors and a Principal at BioTrack Capital. "I believe companies who are leading their field will emerge triumphant in their mission. I am confident that OnCusp is one of those companies." About OnCusp Therapeutics OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients. About CUSP06 CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a highly stable and homogenous ADC. The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased "bystander effect" compared to competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics. WuXi XDC, a global CRDMO company dedicated to end-to-end bioconjugates services, is the CMC partner for CUSP06. CONTACT: zhuli huang, vv.huang@va-topcreative.com
HONG KONG, Jan. 4, 2024 /PRNewswire/ -- ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"), a B2B electronic component products e-commerce platform, announced today that the Company has completed an extensive SaaS enhancement of its one-stop components procurement platform to support customer growth. ICZOOM's SaaS enhancement further integrates R&D, operations, financial accounting and intelligent management systems for more efficient and streamlined enterprise workflow transactions. The enhancements also more tightly integrate support of blockchain technology, more robust security protocols and supply chain ERP management cloud platform service. Additionally, the new SaaS enhancement provides more feature-rich automated analytics, reporting, notification options, and intelligent management systems. ICZOOM's CEO, Mr. Lei Xia, commented, "We are enabling the digital transformation of a growing number of customers' component procurement systems. Our leadership and commitment to investing in support of the small and medium-sized microelectronics enterprises we serve are driving ICZOOM's growth as we help customers to purchase electronic components more conveniently, reduce procurement costs and improve procurement efficiency. At the same time, this is helping us to build and fortify our competitive advantage, which is important to our long-term success as we work to build value for shareholders." About ICZOOM Group Inc. ICZOOM Group Inc. (Nasdaq: IZM) is primarily engaged in sales of electronic component products to customers in Hong Kong and mainland China through its B2B e-commerce platform. These products are primarily used by China based small and medium-sized enterprises ("SMEs") in the consumer electronic industry, Internet of Things ("IoT"), automotive electronics and industry control segments. By utilizing latest technologies, the Company's platform collects, optimizes and presents product offering information from suppliers of all sizes, all transparent and available to its SME customers to compare and select. In addition to the sales of electronic component products, the Company also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance. For more information, please visit the Company's website: http://ir.iczoomex.com/index.html. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "should," "will," "could" and similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.
A12 藝術空間
investors
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
